Skip to content
BioSupply Trends Quarterly logo
  • About Us
  • About Us
Subscribe
  • News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
BioSupply Trends Quarterly logo

HHS Finalizes Rule Expanding Access to Care and Increasing Protections for Medicare Part D Plans

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare and Medicaid Services (CMS), is finalizing policies to ensure Medicare Advantage and Medicare Part D prescription drug plans best meet the needs of people with Medicare. 

New Rule Expands Access to Health Information and Improves Prior Authorization Process

image of medical health record

CMS finalized the CMS Interoperability and Prior Authorization Final Rule to improve the electronic exchange of health information and prior authorization processes for medical items and services.

CMS Finalizes Rule to Advance Health Equity

image of health equity text

CMS finalized policies to support primary care, advance health equity, assist family caregivers and expand access to behavioral and certain oral healthcare.

$13M NIH Grant Funds Research to Rejuvenate Immune System in Older Adults

image of older women

University of Arizona Health Sciences researchers have received a $13.1 million grant from the National Institute on Aging to continue studies aimed at rejuvenating the immune system of older people to improve health throughout the lifespan.

New Guidance Recommends All Federal Facilities Have Access to Naloxone

image of naloxone

The U.S. Department of Health and Human Services and the General Services Administration have announced new guidance recommending that all federal facilities across the nation include overdose reversal medications in their safety stations on site.

HHS Awards $45 Million in Grants to Expand Access to Care for People with Long COVID

HHS Awards $45 Million in Grants to Expand Access to Care for People with Long COVID

The U.S. Department of Health and Human Services announced nine grant awards $1 million each for up to five years to support existing multidisciplinary Long COVID clinics across the country.

Evidence-Based Teen Pregnancy Prevention Programs Receive HHS Awards

Evidence-Based Teen Pregnancy Prevention Programs Receive HHS Awards

The U.S. Department of Health and Human Services (HHS) announced approximately $23 million in funding to foster innovation, provide new research and expand the evidence to support and advance equity in the Teen Pregnancy Prevention program.

First Drugs Selected for Medicare Drug Price Negotiation

First Drugs Selected for Medicare Drug Price Negotiation

The U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D selected for negotiation as part of the Inflation Reduction Act.

OCR Issues Resources to Educate Patients about Telehealth and the Privacy and Security of Protected Health Information

Telehealth and the Privacy and Security of Protected Health Information

The Office for Civil Rights (OCR) at the U.S. Department of Health and Human Services has issued two resource documents to help explain to patients the privacy and security risks to their protected health information when using telehealth services and ways to reduce these risks.

HHS Forms the Office of Long COVID Research and Practice and Launch of Long COVID Clinical Trials

HHS Forms the Office of Long COVID Research and Practice and Launch of Long COVID Clinical Trials

The U.S. Department of Health and Human Services has founded the Office of Long COVID Research and Practice to lead the Long COVID response and coordination across the federal government. In addition, the National Institutes of Health launched Long COVID clinical trials through the RECOVER Initiative.

← Previous
Next →
BioSupply Trends Quarterly logo
FFF Enterprises logo
  • Current Issue
  • Past Issues
  • Resources
  • Current Issue
  • Past Issues
  • Resources
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
Facebook-f Linkedin-in

FFF Enterprises.com | Privacy Statement | Terms of Use | California Consumer Privacy Act (CCPA) Opt-Out Icon

FFF Enterprises.com
Privacy Statement
Terms of Use
California Consumer Privacy Act (CCPA) Opt-Out Icon

©2024 FFF Enterprises, Inc. All Rights Reserved. Property of FFF Enterprises, Inc.

The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.